Ascendis Pharma A/S To Present At The Leerink Partners Global Healthcare Conference

COPENHAGEN, Denmark, Feb. 3, 2016 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced plans to present at an upcoming investor conference.


2016 Leerink Partners Global Healthcare Conference


Waldorf Astoria, New York, NY


Wednesday, February 10, 2016


11:55am EST

An audio webcast of this event will be posted to the Investor Relations section of the Ascendis Pharma website at

About Ascendis Pharma A/S

Ascendis Pharma is applying its innovative TransCon technology to develop an internal pipeline of therapeutics to address unmet medical needs in rare disease indications carrying billion-dollar potential.  The Ascendis Pharma internal pipeline consists of existing parent drugs with known pharmacology, and features TransCon Growth Hormone, a wholly-owned program that has completed Phase 2 studies in adults and children with growth hormone deficiency.  TransCon Growth Hormone is expected to enter a pivotal Phase 3 pediatric study in mid-2016. 

Additionally, Ascendis Pharma has formed collaborations with Sanofi in diabetes and Genentech in the field of ophthalmology, which are focused on developing leading products in large markets of strategic importance to these partners. 

The TransCon technology combines the benefits of prodrug and sustained release technologies, and is the key driver of Ascendis' mission to develop a pipeline of therapeutics with best-in-class profiles. The TransCon technology can be applied to a broad range of drug therapies, including proteins, peptides and small molecules, to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug.

Investor contact:
Martin Auster, M.D.
Chief Business Officer
(650) 352-8389

Ascendis Pharma logo

Logo -


To view the original version on PR Newswire, visit:

SOURCE Ascendis Pharma A/S

Back to news